Evidence map›Paper›PMID 40000368›Full record

Trial reportRenal failure2025

Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia.

Tian Xu, Yilin Ruan, Na Liu, Yi Wang, Xiujuan Zang, Yuhua Ma, Hualin Qi, Xiuhua Mi, Geping Yu, Chunyan Zhang and 4 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tian XuDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yilin RuanDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Na LiuDepartment of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Yi WangDepartment of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Xiujuan ZangDepartment of Nephrology, Shanghai Songjiang District Central Hospital, Shanghai, China.
Yuhua MaDepartment of Nephrology, Traditional Chinese Medicine Hospital of Kunshan, Kunshan, Jiangsu, China.
Hualin QiDepartment of Nephrology, The People's Hospital of Pudong New District in Shanghai, Shanghai, China.
Xiuhua MiDepartment of Nephrology, Shanghai Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Geping YuDepartment of Nephrology, Tonglu First People's Hospital, Tonglu, Hangzhou, China.
Chunyan ZhangDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaomin HuangDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jingyuan XieDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Nan ChenDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hong RenDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo observe the effect of roxadustat on lowering blood lipids in peritoneal dialysis (PD) patients beyond treating anemia.

methodsIn a prospective, multicenter clinical study, we randomly assigned (in a 1:1 ratio) 100 PD patients who had received erythropoiesis-stimulating agent therapy for at least 4 weeks to receive either roxadustat or erythropoietin (EPO) for 48 weeks. The blood lipids, hemoglobin, blood pressure, blood glucose, iron metabolism and inflammatory factors were compared between the two groups at 0, 2, 4, 8, 12, 16, 20, 24 and 48 weeks, respectively.

resultsAt start of switching to roxadustat, hemoglobin seemed to rise a little faster (102.8 ± 15.4 vs. 97.1 ± 17.3 g/L at 2 weeks,

conclusionsRoxadustat not only can improve anemia and iron metabolism, but also can reduce serum cholesterol and triglyceride levels in PD patients after switching from the EPO.

Indexed as

AnemiaGlycineHematinicsIsoquinolinesKidney Failure, ChronicLipidsPeritoneal DialysisAdultAgedErythropoietinFemaleHemoglobinsHumansMaleMiddle AgedProspective StudiesErythropoietinGlycineHematinicsHemoglobinsIsoquinolinesLipidsroxadustatTriglyceridesanemiablood lipidsiron metabolismperitoneal dialysisRoxadustat

Identifiers

PMID40000368
PMCPMC11864003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.